OCUL vs RARE: stock comparison and AI forecast
Ocular Therapeutix, Inc (OCUL) and Ultragenyx Pharmaceutical Inc. (RARE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
OCUL Ocular Therapeutix, Inc
- Price
- $7.14 -26.5% · 6M
- Market Cap
- $1.41B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RARE Ultragenyx Pharmaceutical Inc.
- Market Cap
- $1.54B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- OCUL and RARE have similar market capitalizations ($1.41B and $1.54B).
- RARE turns -88.1% of its revenue into net income, against -579.1% for OCUL.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | OCUL | RARE |
|---|---|---|
| Market Cap | $1.41B | $1.54B |
| P/B Ratio | 2.72x | – |
| EPS | $-1.38 | $-5.18 |
| Book Value/Share | $2.37 | – |
| Revenue/Share | $0.24 | $6.03 |
| FCF/Share | $-1.16 | $-4.48 |
Profitability & Margins
| Metric | OCUL | RARE |
|---|---|---|
| ROE | -58.0% | – |
| ROA | -44.9% | -44.1% |
| ROIC | -50.5% | -58.6% |
| Gross Margin | 87.1% | – |
| Operating Margin | -603.0% | -78.6% |
| Net Margin | -579.1% | -88.1% |
| EBT Margin | -603.0% | -89.1% |
| Tax Rate | – | 1.2% |
Financial Health
| Metric | OCUL | RARE |
|---|---|---|
| Current Ratio | 13.11x | 1.40x |
| Quick Ratio | 13.03x | 1.25x |
| D/E Ratio | 0.29x | – |
| Financial Leverage | 1.29x | – |
| Interest Coverage | -37.8x | -32.5x |
| Working Capital | $595M | $155M |
Cash Flow
| Metric | OCUL | RARE |
|---|---|---|
| Operating Cash Flow | -$238M | -$437M |
| Free Cash Flow | -$255M | -$442M |
| Capital Spending | -$17M | -$5M |
| FCF/Sales | -490.1% | -74.3% |
| CapEx/Sales | 32.4% | 0.8% |
Operational Efficiency
| Metric | OCUL | RARE |
|---|---|---|
| Asset Turnover | 0.08x | 0.50x |
| Receivables Turnover | 1.7x | 3.6x |
| Inventory Turnover | 1.8x | – |
| Fixed Assets Turnover | 2.7x | 2.6x |
| Days Sales Outstanding | 212 days | 102 days |
| Days Inventory | 208 days | – |
| Payables Period | 381 days | – |
| Cash Conversion Cycle | 40 days | – |
Income Statement
| Metric | OCUL | RARE |
|---|---|---|
| Total Revenue | $52M | $594M |
| Operating Income | -$314M | -$467M |
| Net Income | -$301M | -$524M |
| R&D Expense | $224M | $711M |
| SG&A Expense | $247M | $361M |
| Cost of Goods Sold | $7M | – |
Dividend & Shareholder Information
| Metric | OCUL | RARE |
|---|---|---|
| Shares Outstanding | 220M | 99M |
OCUL vs RARE: stock comparison and AI forecast
Which is bigger, OCUL or RARE?
OCUL and RARE have similar market capitalizations ($1.41B and $1.54B).
Which one does Intratio's AI model rank higher, OCUL or RARE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.